MHB088C Phase I/II Study for Advanced Solid Tumors at 2024 ASCO

Dr. Lin Shen from Beijing Cancer Hospital is set to showcase groundbreaking findings at the ASCO Annual Meeting in Chicago, focusing on the Phase I/II clinical trial of MHB088C. This innovative antibody-drug conjugate (ADC), developed by Minghui Pharmaceutical, Inc., targets the B7-H3 protein and is designed to combat recurrent or metastatic solid tumors. The study's results will be presented in an oral session under the title "Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors."

MHB088C is a product of Minghui's SuperTopoiTM ADC platform and stands out for its potency. The proprietary payload is significantly more powerful than the standard Dxd, offering a bystander effect while mitigating the risk of interstitial lung disease. Coupled with Minghui's B7-H3 antibody, which surpasses competitors in binding and internalization, MHB088C has shown impressive anti-tumor efficacy across various cancers. In xenograft models, it proved to be 3 to 10 times more effective in destroying tumor cells than competing compounds.

The preclinical GLP tox studies highlighted an exceptional safety profile for MHB088C, with no unique toxicities reported, especially no pulmonary issues. The highest non-severely toxic dose was established at 30 mg/kg, administered bi-weekly over seven doses. Since the first patient's enrollment on June 20, 2023, the trial has enrolled over 150 patients with diverse tumor types, all of whom have received at least one dose of MHB088C. The drug has shown promising efficacy and a favorable safety profile, leading to expectations for registrational trials for specific tumor types by year-end.

Minghui Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company committed to developing pioneering treatments for oncology and autoimmune diseases. The company's expertise and proprietary technology platforms are driving the development of a diverse clinical-stage pipeline with first-in-class or best-in-class product candidates.